Provided by Tiger Fintech (Singapore) Pte. Ltd.

Senti Biosciences, Inc.

1.65
+0.05503.46%
Volume:70.31K
Turnover:113.69K
Market Cap:43.03M
PE:-0.31
High:1.66
Open:1.57
Low:1.57
Close:1.59
52wk High:16.94
52wk Low:1.46
Shares:26.16M
Float Shares:9.58M
Volume Ratio:0.86
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3578
EPS(LYR):-12.0350
ROE:-169.54%
ROA:-45.98%
PB:1.75
PE(LYR):-0.14

Loading ...

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing the Phase 2 Dose and Schedule Selection for Senti-202 in Its Clinical Trial for Acute Myeloid Leukemia

THOMSON REUTERS
·
Aug 12

Senti Biosciences Q2 EPS $(0.56) Beats $(0.90) Estimate

Benzinga
·
Aug 07

Senti Biosciences Reports Q2 2025 Financial Results: Cash Holdings Decrease to $21.6M, R&D Expenses Rise by $0.8M

Reuters
·
Aug 07

BRIEF-Senti Biosciences Q2 Net Income USD -14.733 Million

Reuters
·
Aug 07

Senti Biosciences Q2 Operating Income USD -16.798 Million

THOMSON REUTERS
·
Aug 07

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 Senti-202 Study in Acute Myeloid Leukemia (Aml) Expected Q4 2025

THOMSON REUTERS
·
Aug 07

BRIEF-Senti Bio Determines Recommended Phase 2 Dose (RP2D) In Phase 1 Study Of Senti-202

Reuters
·
Aug 05

Senti Bio confirms recommended RP2D in Phase 1 study of SENTI-202

TIPRANKS
·
Aug 05

Senti Biosciences Inc - Senti-202 Well-Tolerated, No Dose Limiting Toxicities

THOMSON REUTERS
·
Aug 05

Senti Bio Determines Recommended Phase 2 Dose (Rp2d) in Phase 1 Study of Senti-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

THOMSON REUTERS
·
Aug 05

Senti Biosciences - Expects to Report Clinical Data, Including Efficacy & Durability, From Expansion Cohort Before Year-End

THOMSON REUTERS
·
Aug 05

Senti Biosciences Inc. Files Initial Statement of Beneficial Ownership for Director Bryan Daniel Baum

Reuters
·
Jul 22

Senti Biosciences Inc. Announces Bryan Baum's Appointment to Board of Directors, Highlighting Strategic Leadership Expansion

Reuters
·
Jul 18

Senti Biosciences Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
Jul 01

Senti Bio participates in Nasdaq Amplify Spotlight Series

TIPRANKS
·
Jun 30

Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment

MT Newswires Live
·
Jun 18

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 12

Senti Biosciences Initiated at Buy by Laidlaw & Co.

Dow Jones
·
Jun 06

Senti Bio initiated with a Buy at Laidlaw

TIPRANKS
·
Jun 06

Press Release: Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

Dow Jones
·
May 22